Provided by the Ig National Society, Inc.
Original Release Date: June 6, 2025
Expiration Date: June 6, 2028
Target Audience
This activity is intended for nurses, pharmacists, and physicians who treat patients with myositis.
Educational Objectives
Part 1 – Primary Immunodeficiency – An Overview
Upon completion of this activity, participants should be able to:
- Discuss the components of our immune system.
- Describe a typical antibody deficiency syndrome that is treated with immunoglobulin.
- Describe the impact of Ig replacement on the health of patients with PI.
Part 2 – Autoinflammatory Disorders
Upon completion of this activity, participants should be able to:
- Define autoinflammatory disorders.
- Discuss the role of phenotyping and family history in diagnosis.
- Describe the basics of inflammasome mediated inflammation.
- Describe the role of cytokine-targeting biologics as therapy for these disorders.
Part 3 – The Complex Primary Immunodeficiency Patient
Upon completion of this activity, participants should be able to:
- Review the range of disorders of host defense.
- Identify the non-infectious co-morbidities associated with PI.
- Recognize that pediatric and adult PI patients are subject to distinct but overlapping clinical problems.
- Explain how complexity in a PI patient derives from multiple, interacting problems.
Part 4 – Pulmonary Complications of Primary Immunodeficiency
Upon completion of this activity, participants should be able to:
- Explain key aspects of the pathogenesis and clinical presentation of pulmonary disease in primary immunodeficiency.
- Summarize our understanding of asthma and chronic obstructive pulmonary disease in primary immunodeficiency.
- Recognize the physiology, clinical presentation, and therapeutic approach to bronchiectasis in primary immunodeficiency.
- Identify distinct forms of interstitial lung disease occurring in primary immunodeficiency.
Part 5 – Immune Dysregulation
Upon completion of this activity, participants should be able to:
- Discuss non-infectious presentations and manifestations of primary immunodeficiency.
- Formulate a differential diagnosis for children with suspected immunodeficiency.
- Identify new rare defects of the immune system that cause immunodeficiency.
Part 6 – Secondary Immune Deficiences from Biological Agents
Upon completion of this activity, participants should be able to:
- Review the nomenclature for monoclonal antibodies.
- Explain the mechanisms for prolonged hypogammaglobulinemia with biologic therapy.
- Review the immune and infectious consequences of some of the most frequently used biologics on the immune system.
- Review the adverse effects of immune check point inhibitors.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Immunoglobulin National Society (IgNS). IgNS is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
IgNS designates this activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 4.25 contact hours.
Pharmacy Continuing Education
IgNS designates this continuing education activity for 4.25 contact hour(s) (0.425 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008390-0000-25-028-H01-P)
Type of Activity: Knowledge
Faculty & Disclosures
IgNS requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to IgNS policies. Others involved in the planning of this activity have no relevant financial relationships.
Faculty
Eleni Tiniakou, MD
Associate Professor of Medicine
Division of Rheumatology
UT Health Science Houston
McGovern Medical School
Conflicts of Interest: Has no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
Participation in this self-study activity should be completed in 4 hours and 15 minutes. To successfully complete activities and receive CE credit, learners must follow these steps:
- Review the objectives and disclosures.
- Study the educational content.
- Complete the activity evaluation.
- Upon completion of all evaluation questions your credit will be made available for download immediately.
For Pharmacists: Upon successfully completing the evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.